Sevoflurane In Acute Myocardial Infarction
Phase 2
Completed
- Conditions
- Acute Myocardial Infarction
- Interventions
- Registration Number
- NCT00971607
- Lead Sponsor
- Lawson Health Research Institute
- Brief Summary
Ischemic postconditioning can reduce myocardial injury following myocardial infarction.
A potential pharmacological agent is the anesthetic Sevoflurane. The investigators' hypothesis is that sevoflurane during primary percutaneous coronary intervention (PCI) will reduce infarct size.
- Detailed Description
Patients with first STEMI that will be treated by primary PCI, will be randomized to sedation with Sevoflurane during the procedure or to usual care.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- First STEMI, presenting within 6 hours after the onset of chest pain
- Symptoms lasting > 30 minutes
- Persistent ST-segment elevation > 0.1 mV in 2 or more contiguous leads
Exclusion Criteria
- Hypersensitivity to sevoflurane or other halogenated agents
- Malignant hyperthermia
- Cardiac arrest
- Cardiogenic shock
- Previous myocardial infarction or coronary bypass surgery
- Pre-infarction angina
- Heart failure (NYHA III/IV)
- Chronic inflammatory disease
- Severe renal impairment
- Hepatic dysfunction
- Use of Glyburide
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 Oxygen (placebo) Oxygen 1 Oxygen + Sevoflurane Sevoflurane
- Primary Outcome Measures
Name Time Method Infarct size by area under the curve of cardiac markers. 3 days
- Secondary Outcome Measures
Name Time Method ST segment elevation resolution 90 minutes Left ventricular function. Six month TIMI flow 60 minutes CRP 24 hours Patient satisfaction 1 hour Renal function 48 hours
Trial Locations
- Locations (1)
London Health Sceinces Centre
🇨🇦London, Ontario, Canada